Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial

JAMA

Volumn 311, Issue 1, 2014, Pages 33-44

  Dysken, Maurice W ^a   Sano, Mary ^b   Asthana, Sanjay ^c   Vertrees, Julia E ^d   Pallaki, Muralidhar ^e,f   Llorente, Maria ^g   Love, Susan ^a   Schellenberg, Gerard D ^h   McCarten, J Riley ^a   Malphurs, Julie ⁱ   Prieto, Susana ⁱ   Chen, Peijun ^e,f   Loreck, David J ^j,k   Trapp, George ^l   Bakshi, Rajbir S ^l   Mintzer, Jacobo E ^m,n,o   Heidebrink, Judith L ^p   Vidal Cardona, Ana ^q   Arroyo, Lillian M ^q   Cruz, Angel R ^j   Zachariah, Sally ^j   Kowall, Neil W ^r   Chopra, Mohit P ^r   Craft, Suzanne ^s,t   Thielke, Stephen ^s,t   Turvey, Carolyn L ^u,v   Woodman, Catherine ^u,v   Monnell, Kimberly A ^j   Gordon, Kimberly ^j   Tomaska, Julie ^a   Segal, Yoav ^a   Peduzzi, Peter N ^w,x   Guarino, Peter D ^w,x   more..

^a VA MEDICAL CENTER   (United States)

^b James J Peters Medical Center   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d University of New Mexico   (United States)

^e LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

^k UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^l VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^m RALPH H JOHNSON VA MEDICAL CENTER   (United States)

ⁿ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^o Roper St Francis Healthcare   (United States)

^p VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^q VA Caribbean Healthcare System Puerto Rico   (Puerto Rico)

^r VA BOSTON HEALTHCARE SYSTEM   (United States)

^s VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^t UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^u VETERANS AFFAIRS MEDICAL CENTER   (United States)

^v UNIVERSITY OF IOWA   (United States)

^w VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^x YALE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE; ANTIOXIDANT; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLEEDING; CAREGIVER BURDEN; CAUSE OF DEATH; CHARLSON COMORBIDITY INDEX; COGNITION; COMORBIDITY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; GENE FREQUENCY; GENOTYPE; HEART FAILURE; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; VERY ELDERLY; CAREGIVER; DRUG COMBINATION; MIDDLE AGED; NURSING; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIOXIDANTS; CAREGIVERS; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAMIN E;

EID: 84891945394     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.282834     Document Type: Article

References (39)

1. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336(17):1216-1222.
2. Petersen RC, Thomas RG, Grundman M, et al Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388.
3. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-1341.
4. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Memantine treatment in patients with moderate-to-severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-324.
5. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704-715.
6. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83-89.
7. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2008;13(1):97-107.
8. Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine inmild Alzheimer disease. Arch Neurol. 2011;68(8):991-998.
9. Dysken MW, Guarino PD, Vertrees JE, et al. Vitamin E and memantine in Alzheimer's disease: clinical trialmethods and baseline data [published online April 11, 2013]. Alzheimers Dement. doi:10.1016/j.jalz.2013.01.014.
10. McKhann G, Drachman DD, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
12. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(2)(suppl 2):S33-S39.
13. Oremus M, Perrault A, Demers L, Wolfson C. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of global scales. J Geriatr Psychiatry Neurol. 2000;13(4):197-205.
14. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983;19(3):448-450.
15. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356-1364.
16. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-2314.
17. Davis KL, Marin DB, Kane R, et al. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12(10):978-988.
18. Stern Y, Albert SM, Sano M, et al. Assessing patient dependence in Alzheimer's disease. J Gerontol. 1994;49(5):M216-M222.
19. Lonn E, Bosch J, Yusuf S, et al HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA . 2005;293(11):1338-1347.
20. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75(4):800-802.
21. Kalbfleish JD, Prentice PL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
22. Odell PM, Anderson KM, D'Agostino RB. Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model. Biometrics. 1992;48(3):951-959.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
24. Rigler SK, Studenski S, Wallace D, Reker DM, Duncan PW. Co-morbidity adjustment for functional outcomes in community-dwelling older adults. Clin Rehabil. 2002;16(4):420-428.
25. Studenski SA, Lai SM, Duncan PW, Rigler SK. The impact of self-reported cumulative comorbidity on stroke recovery. Age Ageing. 2004;33(2): 195-198.
26. Grill JD, Karlawish J. Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther. 2010;2(6):34.
27. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementationmay increase all-cause mortality. Ann Intern Med. 2005;142(1):37-46.
28. Dysken MW, Kirk LN, Kuskowski M. Changes in vitamin E prescribing for Alzheimer patients. Am J Geriatr Psychiatry. 2009;17(7):621-624.
29. Farrer LA, Cupples LA, Haines JL, et al APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: ameta-analysis. JAMA. 1997;278(16):1349-1356.
30. Jun G, Naj AC, Beecham GW, et al Alzheimer's Disease Genetics Consortium. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010;67(12):1473-1484.
31. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD: the Galantamine USA-10 Study Group. Neurology. 2000;54(12):2269-2276.
32. Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;20(2-3):120-132.
33. Zhu CW, Scarmeas N, Torgan R, et al. Clinical characteristics and longitudinal changes of informal cost of Alzheimer's disease in the community. J Am Geriatr Soc. 2006;54(10):1596-1602.
34. Zhu CW, Scarmeas N, Torgan R, et al. Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology. 2006;67(6):998-1005.
35. Potkin SG. The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. Int Psychogeriatr. 2002;14(suppl 1):7-26.
36. Knopman DS, Berg JD, Thomas R, Grundman M, Thal LJ, Sano M. Nursing home placement is related to dementia progression: experience from a clinical trial: Alzheimer's Disease Cooperative Study. Neurology. 1999;52(4):714-718.
37. Smith GE, Kokmen E, O'Brien PC. Risk factors for nursing home placement in a population-based dementia cohort. J Am Geriatr Soc. 2000;48(5):519-525.
38. Miller EA, Schneider LS, Rosenheck RA. Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation. Int Psychogeriatr. 2011;23(1):44-53.
39. Semla T. Updated criteria for use: memantine to treat dementia. VHA Pharmacy Benefits Management Service and the Medical Advisory Panel. http://www.pbm.va.gov/PBM/clinicalguidance/criteriaforuse.asp.Accessed September 15, 2013.